Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06472076 · ClinicalTrials.gov registry record · Phase 3

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

A Phase 3 study of Lung Cancer, Non-Small Cell, sponsored by GlaxoSmithKline.

Active
Registry status
Phase 3
Development phase
88
Enrollment target
20
Study locations

NCT06472076: Active Phase 3 study of Lung Cancer, Non-Small Cell, sponsored by GlaxoSmithKline.

NCT06472076 is a Phase 3 study of Lung Cancer, Non-Small Cell that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 88 participants, below the 450-participant average among 16 other Lung Cancer, Non-Small Cell trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06472076, a Phase 3 study of Lung Cancer, Non-Small Cell, is active but no longer recruiting, sponsored by GlaxoSmithKline.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
88 participants
Enrollment target
20
Study locations

Study Summary

The goal of this clinical trial is to evaluate the safety and tolerability profile of dostarlimab in combination with belrestotug when compared with pembrolizumab and placebo in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1 high NSCLC.

Conditions Studied

Lung Cancer, Non-Small Cell

Interventions

  • BIOLOGICAL Pembrolizumab
  • DRUG Placebo
  • BIOLOGICAL Dostarlimab
  • BIOLOGICAL Belrestotug

Study Locations (20)

Other

  • GSK Investigational Site - Buenos Aires
  • GSK Investigational Site - Cipoletti Rio Negro
  • GSK Investigational Site - Ciudad Autonoma de Buenos Aire
  • GSK Investigational Site - Ciudad Autonoma de Bueno
  • GSK Investigational Site - Córdoba
  • GSK Investigational Site - Florida
  • GSK Investigational Site - Mendoza
  • GSK Investigational Site - Rosario
  • GSK Investigational Site - Rosario
  • GSK Investigational Site - San Miguel de Tucumán
  • GSK Investigational Site - Hasselt

Kentucky

  • GSK Investigational Site - Lexington
  • GSK Investigational Site - Lexington

Florida

  • GSK Investigational Site - Ocala

Hawaii

  • GSK Investigational Site - Honolulu

Michigan

  • GSK Investigational Site - Ann Arbor

Nebraska

  • GSK Investigational Site - Omaha

Tennessee

  • GSK Investigational Site - Nashville

Texas

  • GSK Investigational Site - Fort Worth

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2024-06-10
Est. Completion 2027-02-02
Phase Phase 3
GlaxoSmithKline

1,345 total trials

What the registry record for NCT06472076 still lists

NCT06472076 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 450-participant average among 16 other Lung Cancer, Non-Small Cell trials with a reported enrollment target (80% lower).

The record links to 1 condition, with Lung Cancer, Non-Small Cell appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT06472076 names 20 study sites across 9 states, led by Other, Kentucky, Florida.

Frequently Asked Questions

What is clinical trial NCT06472076 about?

NCT06472076 is a clinical study titled "A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)". The goal of this clinical trial is to evaluate the safety and tolerability profile of dostarlimab in combination with belrestotug when compared with pembrolizumab and placebo in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1 high NSCLC.

What is the current status of trial NCT06472076?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 88 participants. The study started on 2024-06-10. Estimated completion is 2027-02-02.

What conditions does trial NCT06472076 study?

This clinical trial studies the following conditions: Lung Cancer, Non-Small Cell.

What interventions are being tested in trial NCT06472076?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Placebo (DRUG), Dostarlimab (BIOLOGICAL), Belrestotug (BIOLOGICAL).

Who is sponsoring clinical trial NCT06472076?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06472076 being conducted?

This trial has 20 study locations across Florida, Hawaii, Kentucky, Michigan, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer, Non-Small Cell

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06472076's enrollment target sits among peer trials

88 11th of 16 higher than 6 of 16 other Lung Cancer, Non-Small Cell trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Cancer, Non-Small Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03843463 · 88 participants · Phase 2

    Escitalopram and Language Intervention for Subacute Aphasia

  • NCT04066348 · 88 participants · Phase 2

    TNF-α Treatment of Blast-Induced Tinnitus

  • NCT04331704 · 88 participants · Phase 4

    ANCHORS Alcohol & Sexual Health Study: UH3 Project

  • NCT04536103 · 88 participants

    Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06472076, the US trial registry maintained by the National Library of Medicine. NCT06472076 (small enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.